ALLMedicine™ Allergic Conjunctivitis Center

Mar 25th, 2023 - The aim of this study was to evaluate the efficacy of a new immunochromatographic assay (Aifeice) in the diagnosis of allergic conjunctivitis diseases (ACDs) and to explore the relationship between Aifeice testing results and the severity of ACDs....

Mar 22nd, 2023 - The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seaso...

Mar 19th, 2023 - Gel-forming mucins secreted by conjunctival goblet cells have been implicated in the clearance of allergens, pathogens, and debris. However, their roles remain incompletely understood. Here we show that human and mouse conjunctival goblet cell muc...

Mar 17th, 2023 - Observational studies have suggested associations of atopic dermatitis (AD) with conjunctivitis and other ocular surface diseases (OSDs). It is still unclear, however, whether or in which direction causal relationships exist, because these associa...

Mar 16th, 2023 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

Mar 22nd, 2023 - The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seaso...

Mar 16th, 2023 - To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

Mar 16th, 2023 - This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of seasonal allergic ...

Mar 16th, 2023 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

Feb 10th, 2023 - To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:

Oct 21st, 2022 - MONTREAL — Ocular surface disease (OSD) in patients with atopic dermatitis (AD) treated with dupilumab may be exacerbated rather than caused by the therapy, according to a study presented at the annual meeting of the International Society of Atopi...

Oct 13th, 2022 - Allergen immunotherapy (AIT) for allergic rhinitis and asthma is effective long-term, according to a literature review of real-world evidence by researchers in Germany and Poland. "Real-world data for AIT complement those from randomized controlle...

Oct 4th, 2022 - CHICAGO, Illinois — Children who are more physically fit seem to be less prone to eye allergies, according to a study of more than 1 million 10-year-olds in Taiwan that was reported at the annual meeting of the American Academy of Ophthalmology (A...

Sep 7th, 2022 - Patients with both nasal and ocular symptoms of seasonal allergic rhinitis (SAR) have a new treatment option that combines olopatadine hydrochloride and mometasone furoate in the form of a nasal spray. Ryaltris (Hikma Pharmaceuticals PLC and Glenm...

Apr 28th, 2022 - Physical examination revealed an irregularly shaped conjunctival cyst on the lateral (temporal) field of the right eye. (This diagnosis is usually made based on the clinical examination alone.